Clothing and equipage, Army, 1941: hearings before the subcommittee of the Committee on Appropriations, United States Senate, Seventy-seventh Congress, first session, on H.J. Res. 89, a joint resolution making an additional appropriation for the military establishment, fiscal year ending June 30, 1941, [Tuesday, February 4, 1941].

Alva B. Adams, chairman.

Economic summits, 1981-89.

"May 1990."

Legislative history of H.R. 13103 : 89th Congress, Foreign investors tax act of 1966, Public law 89-809 /

Mode of access: Internet.

Proposed St. George Basin, sale 89 : final environmental impact statement /

"MMS 85-0029"--Cover.

Qualified Areas under the Public Works and Economic Development Act of 1965, as Amended, Public Law 89-136

Title Varies: Qualified Areas under the Public Works and Economic Development Act of 1965, Public Law 89-136; Areas Eligible for Financial Assistance Designated under the Public Works and Economic Development Act of 1965; Qualified Areas, Criteria and Data under the Public Works and Economic Development Act of 1965 Public Law 89-136

Saadia Al-fajjûmi's arabische Psalmenübersetzung und Commentar (Psalm 73-89) : nach einer Münchener, einer Berliner und einer Oxforder Handschrift herausgegeben, übersetzt und mit Anmerkungen versehen

von Dr. Siegfried Galliner

Fragm. lat. VI 89 - Breviarium (Septem Machabei)

Trägerband: Ms. lat. oct. 15 Bd. 1; Vorbesitzer: Heinrich Kellner; Johann Maximilian Zum Jungen

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

OBJECTIVE: To evaluate the cost-effectiveness of adding zoledronic acid or strontium-89 to standard docetaxel chemotherapy for patients with castrate-refractory prostate cancer (CRPC).

PATIENTS AND METHODS: Data on resource use and quality of life for 707 patients collected prospectively in the TRAPEZE 2 × 2 factorial randomised trial (ISRCTN 12808747) were used to assess the cost-effectiveness of i) zoledronic acid versus no zoledronic acid (ZA vs. no ZA), and ii) strontium-89 versus no strontium-89 (Sr89 vs. no Sr89). Costs were estimated from the perspective of the National Health Service in the UK and included expenditures for trial treatments, concomitant medications, and use of related hospital and primary care services. Quality-adjusted life-years (QALYs) were calculated according to patients' responses to the generic EuroQol EQ-5D-3L instrument, which evaluates health status. Results are expressed as incremental cost-effectiveness ratios (ICERs) and cost-effectiveness acceptability curves.

RESULTS: The per-patient cost for ZA was £12 667, £251 higher than the equivalent cost in the no ZA group. Patients in the ZA group had on average 0.03 QALYs more than their counterparts in no ZA group. The ICER for this comparison was £8 005. Sr89 was associated with a cost of £13 230, £1365 higher than no Sr89, and a gain of 0.08 QALYs compared to no Sr89. The ICER for Sr89 was £16 884. The probabilities of ZA and Sr89 being cost-effective were 0.64 and 0.60, respectively.

CONCLUSIONS: The addition of bone-targeting treatments to standard chemotherapy led to a small improvement in QALYs for a modest increase in cost (or cost-savings). ZA and Sr89 resulted in ICERs below conventional willingness-to-pay per QALY thresholds, suggesting that their addition to chemotherapy may represent a cost-effective use of resources.

Evaluación de la posición del huevo incubable (día 3, 5 y 7) de los lotes de reproductoras pesadas (88-89-90-91 y 92) de la línea Ross 308

Tesis (Zootecnista). -- Universidad de La Salle. Facultad de Ciencias Agropecuarias. Programa de Zootecnia, 2015

Annual Report Fiscal Year 1988-89

The South Carolina State Ports Authority published an annual report with information about the board and senior management, independent auditor report, and financial statements. This annual report ceased after 2005, although they still publish annual financial statements.